Cosmo is one of the few SIX-listed biopharma companies with cash resources to fund clinical development and pay dividends due to a strong balance sheet and sustainable revenues from eight marketed products. Growth products GI Genius, Winlevi, Breezula are expected to drive significant growth and margin expansion.
Key catalysts include:
1. Investor Day (1 July 2025)
2. Winlevi CHMP re-examination response (Q3 2025)
3. Breezula 6-month topline results phase III AGA trial (early H2 2025)